Skip to main content
OpenTrials
Completed

NCT Number: NCT04882644

Effects of Aerobic Exercise on Lean Non-alcoholic Fatty Liver Disease (NAFLD)

NAFLD is increasingly being identified in lean individuals, especially in Chinese population. Among the NAFLD patients, the lean NAFLD accounts for 15.9%-23.0%. Previous studies showed that the lean NAFLD individuals might have a higher risk of severe hepatic disease than those obese individuals. However, the effects of aerobic exercise on the reduction of liver fat content and metabolic risk factors in lean NAFLD individuals remain unknown. In this randomized controlled trial, we will examine the effect of a 3-month exercise training (aerobic exercise) on liver fat content and metabolic risk factors in lean NAFLD individuals.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-Alcoholic Fatty Liver Disease Digestive System Diseases Fatty Liver Liver Diseases

Age range

30 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital with Nanjing Medical University

Nanjing, China, 210029

About this study

The whole study is divided into four phases: recruitment phase, training phase (1 month, aim to gradually adapt patients to the target exercise intensity), implementation phase (3 months), and follow-up phase (9 months). And the subjects are randomly assigned to two groups: aerobic exercise intervention group and control group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Subjects with NAFLD determined by MRI-PDFF (liver fat>5%).
  • Subjects with BMI<23 kg/m2.
  • Subjects with inactive exercise before.
  • Subjects with basic abilities of understanding, communication and writing.

Exclusion criteria

  • 1. Regular drinkers (consumed more than an average of 140 grams of ethanol per week in men and 70 grams in women during the past twelve months).
  • Complicated with other liver diseases (i.e. acute or chronic viral hepatitis, liver cancer, liver cirrhosis, drug-induced liver diseases, and autoimmune hepatitis).
  • Subjects with abnormal liver function (i.e. more than 3 times the upper limit of normal alanine aminotransferase and aspartate aminotransferase).
  • Complicated with severe cardiovascular disease [i.e. myocardial infarction, arrhythmia, heart failure (New York Heart Association III or IV), uncontrolled hypertension (i.e. systolic blood pressure >180 mmHg, and/or diastolic blood pressure >100 mmHg)].
  • Complicated with severe kidney disease or severe renal insufficiency or tumour.
  • Currently pregnant or planning to be pregnant or breast feeding women.
  • Participating in weight loss programs/exercise programs currently or during the past three months.
  • Having any medical condition that would affect metabolism or limit exercise (i.e. diabetes, known hyperthyroidism or hypothyroidism).
  • Having a medical condition that would limit exercise participation or alter heart rate during exercise or taking medication that would affect metabolism or weight loss (i.e. glucocorticoids, antithyroid drugs, hypoglycemic drugs, antihypertensive drugs).
  • Having been doing regular physical exercise for the past three months (i.e. 3 times/week, >30 min/time).
  • Subjects with poor adherence.

Treatment and study plan

Aerobic Exercise

Behavioral

The subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption three times per week for 60 min/session (including 5 min warm-up and 5 min cool down) with treadmills, ellipticals, and rowing machine. The subjects attend health education sessions (eg, general health knowledge of NAFLD and metabolic diseases, and elements of a healthy lifestyle) monthly in the 12 months.

Primary outcomes

  1. Changes from baseline in the liver fat content at 3 months after intervention.

    Time frame: 3 months

    The magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) is used to detect the liver content. An diagnosis of NAFLD is the liver fat content > 5%.

    Changes = (liver fat content at 3 months after intervention - liver fat content at baseline)

Secondary outcomes

  1. Changes from baseline in body mass index (BMI) at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    The BMI expressed in units of kg/m2 is calculated as the body weight （kilograms） divided by the square of the body height (meters) while height and weight are measured by calibrated instruments with standard protocols.

    Changes = (BMI at 3/12 months after intervention - BMI at baseline).

  2. Changes from baseline in waist hip ratio(WHR) at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    The WHR is calculated as the waist circumference（centimeters）divided by the hip circumference (centimeters) while waist circumference and hip circumference are measured by calibrated instruments with standard protocols.

    Changes = (WHR at 3/12 months after intervention - WHR at baseline).

  3. Changes from baseline in abdominal fat at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    Abdominal fat expressed in units of cm2 is detected by MRI-PDFF.

    Changes = (the values of abdominal fat at 3/12 months after intervention - the values of abdominal fat at baseline).

  4. Changes from baseline in blood pressure at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    Blood pressure is measured by electronic automated sphygmomanometer.

    An normal blood pressure is defined as a systolic blood pressure between 90 and 139 mmHg and a diastolic blood pressure between 60 and 89 mmHg.

    Changes = (blood pressure at 3/12 months after intervention - blood pressure at baseline)

  5. Changes from baseline in triglycerides at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    Triglycerides is detected by fasting blood test.

    Normal triglycerides level is less than 2.26 mmol/L.

    Changes = (triglycerides at 3/12 months after intervention - triglycerides at baseline)

  6. Changes from baseline in total cholesterol at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    Total cholesterol is detected by fasting blood test.

    Normal total cholesterol level is less than 5.20 mmol/L.

    Changes = (total cholesterol at 3/12 months after intervention - total cholesterol at baseline)

  7. Changes from baseline in fasting blood glucose at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    Fasting blood glucose is detected by fasting blood test.

    Normal fasting blood glucose level is a range of 3.90-6.10 mmol/L.

    Changes = (fasting blood glucose at 3/12 months after intervention - fasting blood glucose at baseline)

  8. Changes from baseline in fasting insulin at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    Fasting insulin is detected by fasting blood test.

    Normal fasting insulin level is a range of 1.8-11.8 μU/mL.

    Changes = (fasting insulin at 3/12 months after intervention - fasting insulin at baseline)

  9. Changes from baseline in glucose level for oral glucose tolerance test (OGTT) at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    Participants will fast for at least 10 hours before the test. After a fasting blood sample is drawn, participants will drink 75g glucose in 300 ml water within 3-5 minutes. Blood samples will be drawn at 30 min, 60min and 120 min after glucose loading to measure glucose.

    Normal glucose level for OGTT at 2 hours is <7.8 mmol/L.

    Changes = (glucose level for OGTT at 2 hours at 3/12 months after intervention - glucose level for OGTT at 2 hours at baseline)

  10. Changes from baseline in homeostasis model assessment of insulin resistance (HOMA-IR) at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    HOMA-IR is calculated as [fasting glucose (mmol/L)* fasting insulin (μU/mL) ] / 22.5.

    HOMA-IR < 1 signals optimal insulin sensitivity and HOMA-IR < 2.5 signals normal insulin sensitivity.

    Changes = (HOMA-IR at 3/12 months after intervention - HOMA-IR at baseline)

  11. Changes from baseline in homeostasis model assessment of β-cell function (HOMA-β) at 3/12 months after intervention.

    Time frame: 3 months, 12 months

    HOMA-β is calculated as 20 x fasting insulin(μU/ml)/[fasting glucose (mmol/L) - 3.5].

    Changes = (HOMA-β at 3/12 months after intervention - HOMA-β at baseline)

  12. Changes from baseline in the liver fat content at 12 months after intervention.

    Time frame: 12 months

    The magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) is used to detect the liver content. An diagnosis of NAFLD is the liver fat content > 5%.

    Changes = (liver fat content at 12 months after intervention - liver fat content at baseline)

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital with Nanjing Medical University

Other

Collaborators

  • Nanjing Medical University

Registry information

Official study title

Effects of Aerobic Exercise on Lean Non-alcoholic Fatty Liver Disease

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
May 12, 2021
Registry last updated
Sep 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.